>

Zealand Technical Analysis

<div class='circular--portrait' style='background:#0D8ECF;color: white;font-size:3em;padding-top: 40px;;'>ZEA</div>
ZEAL -- Denmark Stock  

DKK 194.80  13.60  6.53%

As of the 31rd of March Zealand Pharma maintains Market Risk Adjusted Performance of (0.52) and Mean Deviation of 3.28. Relative to Fundamental Indicators, Macroaxis technical analysis interface lets you check existing technical drivers of Zealand Pharma AS as well as the relationship between them. Specifically, you can use this information to find out if the organization will indeed mirror its model of past data patterns or the prices will eventually revert. We found nineteen technical drivers for Zealand Pharma AS, which can be compared to its rivals. Please check out Zealand Pharma AS Downside Deviation, Standard Deviation, Information Ratio, as well as the relationship between Coefficient Of Variation and Variance to decide if Zealand Pharma AS is priced fairly providing market reflects its latest price of 194.8 per share.
View Technical Analysis For
Refresh

Zealand Pharma AS Technical Analysis

Indicator
Time Period
  Portfolio Suggestion    
  
Execute Indicator
 
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Zealand Pharma AS volatility. High ATR values indicate high volatility, and low values indicate low volatility. View also all equity analysis or get more info about average true range volatility indicators indicator.

Zealand Pharma AS Trend Analysis

Use this graph to draw trend lines for Zealand Pharma AS. You can use it to identify possible trend reversals for Zealand Pharma as well as other signals and approximate when it will take place. Remember, you need at least two touches of the trend line with actual Zealand Pharma price movement. To start drawing, click on the pencil icon on top-right. To remove the trend, use eraser icon.

Zealand Pharma Best Fit Change Line

The following chart estimates an ordinary least squares regression model for Zealand Pharma AS applied against its price change over selected period. The best fit line has a slop of   0.72  which may suggest that Zealand Pharma AS market price will keep on failing further. It has 122 observation points and a regression sum of squares at 19560.7, which is the sum of squared deviations for the predicted Zealand Pharma price change compared to its average price change.

Zealand Pharma March 31, 2020 Technical Indicators

Zealand Pharma March 31, 2020 Daily Price Condition

Check out Your Current Watchlist. Please also try Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page